聚焦抗体之外的锆-89 放射性药物研究新趋势。

IF 4.6 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Seminars in nuclear medicine Pub Date : 2024-11-01 DOI:10.1053/j.semnuclmed.2024.10.003

Janie Duvenhage PhD , Maryke Kahts PhD , Beverley Summers PhD , Jan Rijn Zeevaart PhD , Thomas Ebenhan PhD

{"title":"聚焦抗体之外的锆-89 放射性药物研究新趋势。","authors":"Janie Duvenhage PhD , Maryke Kahts PhD , Beverley Summers PhD , Jan Rijn Zeevaart PhD , Thomas Ebenhan PhD","doi":"10.1053/j.semnuclmed.2024.10.003","DOIUrl":null,"url":null,"abstract":"<div><div>Zirconium-89 (<sup>89</sup>Zr) is a cyclotron-produced positron-emitting radioisotope with a half-life of 3.27 days, which makes delayed or longitudinal imaging possible. It is a superior isotope for tracking particles over several days at a high sensitivity, resolution, and specificity. <sup>89</sup>Zr-monoclonal antibodies (<sup>89</sup>Zr-mAb) have gained significant attention in the field of molecular imaging. However, the past decade has shown an avid increase in research concerning <sup>89</sup>Zr-radiopharmaceuticals apart from <sup>89</sup>Zr-mAb. In this article we highlight and discuss the status and challenges attributed to current preclinical and clinical investigations of <sup>89</sup>Zr-radiopharmaceuticals developed beyond <sup>89</sup>Zr-mAb, e.g., mAb-derived variants and macro-biomolecules, proteins, peptides, nanoparticles, and living cells.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 6","pages":"Pages 801-811"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Highlighting New Research Trends on Zirconium-89 Radiopharmaceuticals Beyond Antibodies\",\"authors\":\"Janie Duvenhage PhD , Maryke Kahts PhD , Beverley Summers PhD , Jan Rijn Zeevaart PhD , Thomas Ebenhan PhD\",\"doi\":\"10.1053/j.semnuclmed.2024.10.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Zirconium-89 (<sup>89</sup>Zr) is a cyclotron-produced positron-emitting radioisotope with a half-life of 3.27 days, which makes delayed or longitudinal imaging possible. It is a superior isotope for tracking particles over several days at a high sensitivity, resolution, and specificity. <sup>89</sup>Zr-monoclonal antibodies (<sup>89</sup>Zr-mAb) have gained significant attention in the field of molecular imaging. However, the past decade has shown an avid increase in research concerning <sup>89</sup>Zr-radiopharmaceuticals apart from <sup>89</sup>Zr-mAb. In this article we highlight and discuss the status and challenges attributed to current preclinical and clinical investigations of <sup>89</sup>Zr-radiopharmaceuticals developed beyond <sup>89</sup>Zr-mAb, e.g., mAb-derived variants and macro-biomolecules, proteins, peptides, nanoparticles, and living cells.</div></div>\",\"PeriodicalId\":21643,\"journal\":{\"name\":\"Seminars in nuclear medicine\",\"volume\":\"54 6\",\"pages\":\"Pages 801-811\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in nuclear medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0001299824000886\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299824000886","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

锆-89（89Zr）是一种回旋加速器产生的正电子发射放射性同位素，半衰期为 3.27 天，因此可以进行延迟或纵向成像。它是一种优越的同位素，能以高灵敏度、高分辨率和高特异性追踪粒子数天。89Zr 单克隆抗体（89Zr-mAb）在分子成像领域受到了广泛关注。然而，在过去的十年中，除了 89Zr-mAb 之外，有关 89Zr 放射药物的研究也在急剧增加。在本文中，我们将重点讨论目前对 89Zr-mAb 以外的 89Zr 放射药物（如 mAb 衍生变体和大生物分子、蛋白质、肽、纳米颗粒和活细胞）进行临床前和临床研究的现状和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Highlighting New Research Trends on Zirconium-89 Radiopharmaceuticals Beyond Antibodies

Zirconium-89 (⁸⁹Zr) is a cyclotron-produced positron-emitting radioisotope with a half-life of 3.27 days, which makes delayed or longitudinal imaging possible. It is a superior isotope for tracking particles over several days at a high sensitivity, resolution, and specificity. ⁸⁹Zr-monoclonal antibodies (⁸⁹Zr-mAb) have gained significant attention in the field of molecular imaging. However, the past decade has shown an avid increase in research concerning ⁸⁹Zr-radiopharmaceuticals apart from ⁸⁹Zr-mAb. In this article we highlight and discuss the status and challenges attributed to current preclinical and clinical investigations of ⁸⁹Zr-radiopharmaceuticals developed beyond ⁸⁹Zr-mAb, e.g., mAb-derived variants and macro-biomolecules, proteins, peptides, nanoparticles, and living cells.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in nuclear medicine 医学-核医学

CiteScore

9.80

自引率

6.10%

发文量

审稿时长

14 days

期刊介绍： Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.